10-K Filing

IDEXX LABORATORIES INC /DE CIK: 874716 FY 2014

Filing Information

Form Type	10-K
Accession Number	`0000874716-15-000003`
Period End Date	20141231
Filing Date	20150217
Fiscal Year	2014
Fiscal Period	FY
XBRL Instance	c716-20141231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 88 Income Statement 114 Cash Flow Statement 106 Stockholders Equity 33 Comprehensive Income 39

Balance Sheet 88 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, reserves	`AllowanceForDoubtfulAccountsReceivableCurrent`	$3.53M	USD	Point-in-time
Accounts receivable, reserves	`AllowanceForDoubtfulAccountsReceivableCurrent`	$4.31M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$183.90M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$279.06M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	120.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$322.54M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	120.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$223.99M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	101.95M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	101.19M	shares	Point-in-time
Accounts receivable, net of reserves of $4,306 in 2014 and $3,533 in 2013	`AccountsReceivableNetCurrent`	$158.04M	USD	Point-in-time
Accounts receivable, net of reserves of $4,306 in 2014 and $3,533 in 2013	`AccountsReceivableNetCurrent`	$152.38M	USD	Point-in-time
Inventories	`InventoryNet`	$160.34M	USD	Point-in-time
Inventories	`InventoryNet`	$133.43M	USD	Point-in-time
Deferred stock units, outstanding	`CommonStockOtherSharesOutstanding`	118,000.00	shares	Point-in-time
Deferred stock units, outstanding	`CommonStockOtherSharesOutstanding`	122,000.00	shares	Point-in-time
Treasury stock, shares	`TreasuryStockShares`	54.57M	shares	Point-in-time
Treasury stock, shares	`TreasuryStockShares`	49.65M	shares	Point-in-time
Deferred income tax assets	`DeferredTaxAssetsNetCurrent`	$33.23M	USD	Point-in-time
Deferred income tax assets	`DeferredTaxAssetsNetCurrent`	$37.69M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$86.45M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$48.96M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$652.71M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$759.40M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$303.59M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$281.21M	USD	Point-in-time
Goodwill	`Goodwill`	$180.52M	USD	Point-in-time
Goodwill	`Goodwill`	$172.61M	USD	Point-in-time
Goodwill	`Goodwill`	$184.45M	USD	Point-in-time
Goodwill	`Goodwill`	$174.99M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$65.12M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$58.84M	USD	Point-in-time
Other long-term assets, net	`OtherAssetsNoncurrent`	$71.65M	USD	Point-in-time
Other long-term assets, net	`OtherAssetsNoncurrent`	$57.23M	USD	Point-in-time
Total long-term assets	`AssetsNoncurrent`	$624.81M	USD	Point-in-time
Total long-term assets	`AssetsNoncurrent`	$577.81M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$1.23B	USD	Point-in-time
TOTAL ASSETS	`Assets`	$1.38B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$29.94M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$44.74M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$148.92M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$195.35M	USD	Point-in-time
Line of credit	`LinesOfCreditCurrent`	$277.00M	USD	Point-in-time
Line of credit	`LinesOfCreditCurrent`	$549.00M	USD	Point-in-time
Current portion of long-term debt	`SecuredDebtCurrent`	$1.03M	USD	Point-in-time
Current portion of deferred revenue	`DeferredRevenueCurrent`	$21.46M	USD	Point-in-time
Current portion of deferred revenue	`DeferredRevenueCurrent`	$31.81M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$820.91M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$478.35M	USD	Point-in-time
Deferred income tax liabilities	`DeferredTaxLiabilitiesNoncurrent`	$41.69M	USD	Point-in-time
Deferred income tax liabilities	`DeferredTaxLiabilitiesNoncurrent`	$33.95M	USD	Point-in-time
Long-term debt, net of current portion	`SecuredLongTermDebt`	$350.00M	USD	Point-in-time
Long-term debt, net of current portion	`SecuredLongTermDebt`	$150.36M	USD	Point-in-time
Long-term deferred revenue, net of current portion	`DeferredRevenueNoncurrent`	$21.66M	USD	Point-in-time
Long-term deferred revenue, net of current portion	`DeferredRevenueNoncurrent`	$18.43M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$32.36M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$31.21M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$233.95M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$445.72M	USD	Point-in-time
Total liabilities	`Liabilities`	$712.30M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.27B	USD	Point-in-time
Commitments and Contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 101,947 and 101,188 shares in 2014 and 2013, respectively	`CommonStockValue`	$10.20M	USD	Point-in-time
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 101,947 and 101,188 shares in 2014 and 2013, respectively	`CommonStockValue`	$10.12M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$825.32M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$888.29M	USD	Point-in-time
Deferred stock units: Outstanding: 118 and 122 units in 2014 and 2013, respectively	`CommonStockOtherValueOutstanding`	$5.07M	USD	Point-in-time
Deferred stock units: Outstanding: 118 and 122 units in 2014 and 2013, respectively	`CommonStockOtherValueOutstanding`	$5.11M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.68B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.49B	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-8.07M	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$15.95M	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$13.62M	USD	Point-in-time
Treasury stock, at cost: 54,574 and 49,649 shares in 2014 and 2013, respectively	`TreasuryStockValue`	$1.83B	USD	Point-in-time
Treasury stock, at cost: 54,574 and 49,649 shares in 2014 and 2013, respectively	`TreasuryStockValue`	$2.45B	USD	Point-in-time
Total IDEXX Laboratories, Inc. stockholders' equity	`StockholdersEquity`	$117.52M	USD	Point-in-time
Total IDEXX Laboratories, Inc. stockholders' equity	`StockholdersEquity`	$518.19M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$73.00K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$28.00K	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$636.26M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$539.59M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$518.21M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$117.59M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$1.23B	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$1.38B	USD	Point-in-time

Income Statement 114 line items

Line Item	Tag	Value	Unit	Period
Product revenue	`SalesRevenueGoodsNet`	$816.99M	USD	Annual
Product revenue	`SalesRevenueGoodsNet`	$899.41M	USD	Annual
Product revenue	`SalesRevenueGoodsNet`	$854.53M	USD	Annual
Service revenue	`SalesRevenueServicesNet`	$586.39M	USD	Annual
Service revenue	`SalesRevenueServicesNet`	$476.35M	USD	Annual
Service revenue	`SalesRevenueServicesNet`	$522.53M	USD	Annual
Total revenue	`SalesRevenueNet`	$351.96M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$1.29B	USD	Annual
Total revenue	`SalesRevenueNet`	$1.38B	USD	Annual
Total revenue	`SalesRevenueNet`	$1.49B	USD	Annual
Total revenue	`SalesRevenueNet`	$332.11M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$338.30M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$390.12M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$383.52M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$354.07M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$360.20M	USD	1 Quarter
Total revenue	`SalesRevenueNet`	$352.58M	USD	1 Quarter
Cost of product revenue	`CostOfGoodsSold`	$318.69M	USD	Annual
Cost of product revenue	`CostOfGoodsSold`	$305.91M	USD	Annual
Cost of product revenue	`CostOfGoodsSold`	$335.05M	USD	Annual
Cost of service revenue	`CostOfServices`	$302.25M	USD	Annual
Cost of service revenue	`CostOfServices`	$288.28M	USD	Annual
Cost of service revenue	`CostOfServices`	$334.64M	USD	Annual
Total cost of revenue	`CostOfRevenue`	$620.94M	USD	Annual
Total cost of revenue	`CostOfRevenue`	$594.19M	USD	Annual
Total cost of revenue	`CostOfRevenue`	$669.69M	USD	Annual
Gross profit	`GrossProfit`	$188.66M	USD	1 Quarter
Gross profit	`GrossProfit`	$185.78M	USD	1 Quarter
Gross profit	`GrossProfit`	$202.10M	USD	1 Quarter
Gross profit	`GrossProfit`	$182.16M	USD	1 Quarter
Gross profit	`GrossProfit`	$197.70M	USD	1 Quarter
Gross profit	`GrossProfit`	$699.15M	USD	Annual
Gross profit	`GrossProfit`	$183.97M	USD	1 Quarter
Gross profit	`GrossProfit`	$756.12M	USD	Annual
Gross profit	`GrossProfit`	$213.34M	USD	1 Quarter
Gross profit	`GrossProfit`	$816.12M	USD	Annual
Gross profit	`GrossProfit`	$218.52M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$216.96M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$243.49M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$283.71M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$173.89M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$157.86M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$137.61M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$88.00M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$82.01M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$98.26M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$61.19M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$70.05M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$78.76M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$65.48M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$266.76M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$61.33M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$34.80M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$72.19M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$262.56M	USD	Annual
Income from operations	`OperatingIncomeLoss`	$83.22M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$260.25M	USD	Annual
Interest expense	`InterestExpense`	$5.39M	USD	Annual
Interest expense	`InterestExpense`	$15.43M	USD	Annual
Interest expense	`InterestExpense`	$3.85M	USD	Annual
Interest income	`InterestAndOtherIncome`	$1.90M	USD	Annual
Interest income	`InterestAndOtherIncome`	$1.73M	USD	Annual
Interest income	`InterestAndOtherIncome`	$1.89M	USD	Annual
Income before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$246.56M	USD	Annual
Income before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$260.62M	USD	Annual
Income before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$263.26M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$82.33M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$75.47M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$64.60M	USD	Annual
Net income	`ProfitLoss`	$178.29M	USD	Annual
Net income	`ProfitLoss`	$187.79M	USD	Annual
Net income	`ProfitLoss`	$181.95M	USD	Annual
Less: Net income (loss) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$20.00K	USD	Annual
Less: Net income (loss) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$45.00K	USD	Annual
Less: Net income (loss) attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-6.00K	USD	Annual
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$57.22M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$53.99M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$45.69M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$181.91M	USD	Annual
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$187.80M	USD	Annual
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$178.27M	USD	Annual
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$46.59M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$44.86M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$25.96M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$52.14M	USD	1 Quarter
Net income attributable to IDEXX Laboratories, Inc. stockholders	`NetIncomeLoss`	$43.26M	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.54	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.01	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.12	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$3.63	USD	Annual
Basic	`EarningsPerShareBasic`	$3.24	USD	Annual
Basic	`EarningsPerShareBasic`	$0.87	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.05	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.90	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$3.53	USD	Annual
Basic	`EarningsPerShareBasic`	$0.83	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.82	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.86	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$1.03	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$3.17	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.99	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.82	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.81	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$3.48	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.54	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$3.58	USD	Annual
Diluted	`EarningsPerShareDiluted`	$1.10	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.89	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	54.98M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	50.05M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	53.16M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	50.75M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	56.16M	shares	Annual
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	53.98M	shares	Annual

Cash Flow Statement 106 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$178.29M	USD	Annual
Net income	`ProfitLoss`	$187.79M	USD	Annual
Net income	`ProfitLoss`	$181.95M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$58.89M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$52.41M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$54.60M	USD	Annual
Gain on disposition of pharmaceutical product lines	`DisposalGroupNotDiscontinuedOperationGainLossOnDisposal`	$-3.50M	USD	Annual
Provision for uncollectible accounts	`ProvisionForDoubtfulAccounts`	$1.60M	USD	Annual
Provision for uncollectible accounts	`ProvisionForDoubtfulAccounts`	$1.11M	USD	Annual
Provision for uncollectible accounts	`ProvisionForDoubtfulAccounts`	$2.04M	USD	Annual
Provision for (benefit of) deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$2.07M	USD	Annual
Provision for (benefit of) deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$830.00K	USD	Annual
Provision for (benefit of) deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.97M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$16.54M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$15.95M	USD	Annual
Share-based compensation expense	`ShareBasedCompensation`	$18.10M	USD	Annual
Other	`OtherOperatingActivitiesCashFlowStatement`	$-160.00K	USD	Annual
Other	`OtherOperatingActivitiesCashFlowStatement`	$614.00K	USD	Annual
Other	`OtherOperatingActivitiesCashFlowStatement`	$410.00K	USD	Annual
Tax benefit from share-based compensation arrangements	`ExcessTaxBenefitFromShareBasedCompensationOperatingActivities`	$14.16M	USD	Annual
Tax benefit from share-based compensation arrangements	`ExcessTaxBenefitFromShareBasedCompensationOperatingActivities`	$14.68M	USD	Annual
Tax benefit from share-based compensation arrangements	`ExcessTaxBenefitFromShareBasedCompensationOperatingActivities`	$16.08M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$3.63M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$15.95M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-3.49M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$17.21M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$38.31M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$1.35M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$4.33M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-3.93M	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$25.07M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-2.90M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$6.70M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-4.40M	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$187.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$16.51M	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$36.39M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$6.89M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$6.44M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$14.20M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$246.00M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$222.41M	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$235.85M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$77.61M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$60.52M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$57.62M	USD	Annual
Proceeds from disposition of pharmaceutical product lines	`ProceedsFromSaleOfOtherProductiveAssets`	$3.50M	USD	Annual
Proceeds from disposition of pharmaceutical product lines	`ProceedsFromSaleOfOtherProductiveAssets`	$3.00M	USD	Annual
Proceeds from sale of equity investment	`EquityMethodInvestmentNetSalesProceeds`	$5.40M	USD	Point-in-time
Proceeds from sale of equity investment	`EquityMethodInvestmentNetSalesProceeds`	$-5.40M	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$45.00K	USD	Annual
Acquisitions of intangible assets	`PaymentsToAcquireIntangibleAssets`	$175.00K	USD	Annual
Acquisitions of intangible assets	`PaymentsToAcquireIntangibleAssets`	$900.00K	USD	Annual
Acquisitions of intangible assets	`PaymentsToAcquireIntangibleAssets`	$1.02M	USD	Annual
Acquisitions of a business, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$2.66M	USD	Annual
Acquisitions of a business, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$25.11M	USD	Annual
Acquisitions of a business, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$10.92M	USD	Annual
Net cash used by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-86.06M	USD	Annual
Net cash used by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-80.41M	USD	Annual
Net cash used by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-58.13M	USD	Annual
Borrowings (payments) on revolving credit facilities, net	`ProceedsFromRepaymentsOfOtherDebt`	$-31.00M	USD	Annual
Borrowings (payments) on revolving credit facilities, net	`ProceedsFromRepaymentsOfOtherDebt`	$65.00M	USD	Annual
Borrowings (payments) on revolving credit facilities, net	`ProceedsFromRepaymentsOfOtherDebt`	$272.00M	USD	Annual
Issuance of senior notes	`ProceedsFromIssuanceOfSeniorLongTermDebt`	$200.00M	USD	Annual
Issuance of senior notes	`ProceedsFromIssuanceOfSeniorLongTermDebt`	$150.00M	USD	Annual
Debt issue costs	`DebtIssuanceCosts`	$-1.41M	USD	Annual
Debt issue costs	`DebtIssuanceCosts`	$-976.00K	USD	Annual
Payment of notes payable	`RepaymentsOfSecuredDebt`	$1.39M	USD	Annual
Payment of notes payable	`RepaymentsOfSecuredDebt`	$917.00K	USD	Annual
Payment of notes payable	`RepaymentsOfSecuredDebt`	$1.11M	USD	Annual
Repurchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$618.16M	USD	Annual
Repurchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$132.27M	USD	Annual
Repurchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$367.76M	USD	Annual
Proceeds from exercises of stock options and employee stock purchase plans	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$29.44M	USD	Annual
Proceeds from exercises of stock options and employee stock purchase plans	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$24.17M	USD	Annual
Proceeds from exercises of stock options and employee stock purchase plans	`ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions`	$38.23M	USD	Annual
Tax benefit from share-based compensation arrangements	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$16.08M	USD	Annual
Tax benefit from share-based compensation arrangements	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$14.68M	USD	Annual
Tax benefit from share-based compensation arrangements	`ExcessTaxBenefitFromShareBasedCompensationFinancingActivities`	$14.16M	USD	Annual
Net cash used by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-103.44M	USD	Annual
Net cash used by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-102.45M	USD	Annual
Net cash used by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-125.34M	USD	Annual
Net effect of changes in exchange rates on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$1.16M	USD	Annual
Net effect of changes in exchange rates on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-8.52M	USD	Annual
Net effect of changes in exchange rates on cash	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-2.41M	USD	Annual
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$40.09M	USD	Annual
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$55.07M	USD	Annual
Net increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$43.48M	USD	Annual
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$183.90M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$279.06M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$322.54M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$223.99M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$183.90M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$279.06M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$322.54M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$223.99M	USD	Point-in-time
Interest paid	`InterestPaidNet`	$5.02M	USD	Annual
Interest paid	`InterestPaidNet`	$3.94M	USD	Annual
Interest paid	`InterestPaidNet`	$12.28M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$67.72M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$68.92M	USD	Annual
Income taxes paid	`IncomeTaxesPaidNet`	$60.24M	USD	Annual
Market value of common shares received from employees in connection with share-based compensation - see Note 17	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$4.55M	USD	Annual
Market value of common shares received from employees in connection with share-based compensation - see Note 17	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$4.66M	USD	Annual
Market value of common shares received from employees in connection with share-based compensation - see Note 17	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$5.81M	USD	Annual
Receivable on disposition of pharmaceutical product lines	`NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1`	$3.50M	USD	Annual

Stockholders Equity 33 line items

Line Item	Tag	Value	Unit	Period
Balance, shares	`CommonStockSharesIssued`	101.95M	shares	Point-in-time
Balance, shares	`CommonStockSharesIssued`	101.19M	shares	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$636.26M	USD	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$539.59M	USD	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$518.21M	USD	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$117.59M	USD	Point-in-time
Net income (loss)	`ProfitLoss`	$178.29M	USD	Annual
Net income (loss)	`ProfitLoss`	$187.79M	USD	Annual
Net income (loss)	`ProfitLoss`	$181.95M	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$511.00K	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-2.33M	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-21.69M	USD	Annual
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$178.80M	USD	Annual
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$160.26M	USD	Annual
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$185.46M	USD	Annual
Repurchases of common stock	`StockholdersEquityOther`	$-136.81M	USD	Annual
Repurchases of common stock	`StockholdersEquityOther`	$-623.89M	USD	Annual
Repurchases of common stock	`StockholdersEquityOther`	$-372.19M	USD	Annual
Common stock issued under stock plans, including excess tax benefit, value	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$45.24M	USD	Annual
Common stock issued under stock plans, including excess tax benefit, value	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$51.93M	USD	Annual
Common stock issued under stock plans, including excess tax benefit, value	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$38.67M	USD	Annual
Issuance of deferred stock units	`IssuanceOfDeferredStockUnits`	$142.00K	USD	Annual
Issuance of deferred stock units	`IssuanceOfDeferredStockUnits`	$-332.00K	USD	Annual
Issuance of deferred stock units	`IssuanceOfDeferredStockUnits`	$189.00K	USD	Annual
Share-based compensation cost recognized	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$18.10M	USD	Annual
Share-based compensation cost recognized	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$16.57M	USD	Annual
Share-based compensation cost recognized	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$15.86M	USD	Annual
Balance, shares	`CommonStockSharesIssued`	101.95M	shares	Point-in-time
Balance, shares	`CommonStockSharesIssued`	101.19M	shares	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$636.26M	USD	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$539.59M	USD	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$518.21M	USD	Point-in-time
Balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$117.59M	USD	Point-in-time

Comprehensive Income 39 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$178.29M	USD	Annual
Unrealized (loss) gain on investments, tax (benefit) expense	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax`	$-63.00K	USD	Annual
Net income	`ProfitLoss`	$187.79M	USD	Annual
Unrealized (loss) gain on investments, tax (benefit) expense	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax`	$68.00K	USD	Annual
Unrealized (loss) gain on investments, tax (benefit) expense	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax`	$165.00K	USD	Annual
Net income	`ProfitLoss`	$181.95M	USD	Annual
Unrealized gain (loss), tax (benefit) expense	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-921.00K	USD	Annual
Unrealized gain (loss), tax (benefit) expense	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$4.07M	USD	Annual
Unrealized gain (loss), tax (benefit) expense	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$1.55M	USD	Annual
Foreign currency translation adjustments	`TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease`	$-29.13M	USD	Annual
Reclassification adjustment for gains included in net income, tax expense	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax`	$679.00K	USD	Annual
Foreign currency translation adjustments	`TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease`	$-4.50M	USD	Annual
Reclassification adjustment for gains included in net income, tax expense	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax`	$756.00K	USD	Annual
Foreign currency translation adjustments	`TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease`	$5.67M	USD	Annual
Reclassification adjustment for gains included in net income, tax expense	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax`	$1.62M	USD	Annual
Unrealized (loss) gain on investments, net of tax (benefit) expense of ($63), $165 and $68 in 2014, 2013, and 2012, respectively	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-107.00K	USD	Annual
Unrealized (loss) gain on investments, net of tax (benefit) expense of ($63), $165 and $68 in 2014, 2013, and 2012, respectively	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$116.00K	USD	Annual
Unrealized (loss) gain on investments, net of tax (benefit) expense of ($63), $165 and $68 in 2014, 2013, and 2012, respectively	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$279.00K	USD	Annual
Unrealized gain (loss), net of tax expense (benefit) of $4,073, $1,555 and ($921) in 2014, 2013 and 2012, respectively	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$-1.65M	USD	Annual
Unrealized gain (loss), net of tax expense (benefit) of $4,073, $1,555 and ($921) in 2014, 2013 and 2012, respectively	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$9.54M	USD	Annual
Unrealized gain (loss), net of tax expense (benefit) of $4,073, $1,555 and ($921) in 2014, 2013 and 2012, respectively	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$3.78M	USD	Annual
Less: reclassification adjustment for gains included in net income, net of tax expense of $756, $679 and $1,623 in 2014, 2013 and 2012, respectively	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax`	$2.00M	USD	Annual
Less: reclassification adjustment for gains included in net income, net of tax expense of $756, $679 and $1,623 in 2014, 2013 and 2012, respectively	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax`	$1.89M	USD	Annual
Less: reclassification adjustment for gains included in net income, net of tax expense of $756, $679 and $1,623 in 2014, 2013 and 2012, respectively	`OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax`	$3.62M	USD	Annual
Unrealized gain (loss) on derivative instruments	`OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax`	$-5.28M	USD	Annual
Unrealized gain (loss) on derivative instruments	`OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax`	$1.89M	USD	Annual
Unrealized gain (loss) on derivative instruments	`OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax`	$7.54M	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$511.00K	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-2.33M	USD	Annual
Other comprehensive (loss) income, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-21.69M	USD	Annual
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$178.80M	USD	Annual
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$160.26M	USD	Annual
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$185.46M	USD	Annual
Less: comprehensive income (loss) attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-6.00K	USD	Annual
Less: comprehensive income (loss) attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$20.00K	USD	Annual
Less: comprehensive income (loss) attributable to noncontrolling interest	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$45.00K	USD	Annual
Comprehensive income attributable to IDEXX Laboratories, Inc.	`ComprehensiveIncomeNetOfTax`	$185.47M	USD	Annual
Comprehensive income attributable to IDEXX Laboratories, Inc.	`ComprehensiveIncomeNetOfTax`	$178.78M	USD	Annual
Comprehensive income attributable to IDEXX Laboratories, Inc.	`ComprehensiveIncomeNetOfTax`	$160.21M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.